130 related articles for article (PubMed ID: 34935528)
41. Promoter methylation as biomarkers for diagnosis of melanoma: A systematic review and meta-analysis.
Guo Y; Long J; Lei S
J Cell Physiol; 2019 May; 234(5):7356-7367. PubMed ID: 30370527
[TBL] [Abstract][Full Text] [Related]
42. RASSF1A hypermethylation in pretreatment serum DNA of neuroblastoma patients: a prognostic marker.
Misawa A; Tanaka S; Yagyu S; Tsuchiya K; Iehara T; Sugimoto T; Hosoi H
Br J Cancer; 2009 Jan; 100(2):399-404. PubMed ID: 19165202
[TBL] [Abstract][Full Text] [Related]
43. Promoter methylation of the RASSF1A gene may contribute to colorectal cancer susceptibility: a meta-analysis of cohort studies.
Wang HL; Liu P; Zhou PY; Zhang Y
Ann Hum Genet; 2014 May; 78(3):208-16. PubMed ID: 24621386
[TBL] [Abstract][Full Text] [Related]
44. Association between HIC1 and RASSF1A promoter hypermethylation with MTHFD1 G1958A polymorphism and clinicopathological features of breast cancer in Iranian patients.
Rasti M; Tavasoli P; Monabati A; Entezam M
Iran Biomed J; 2009 Oct; 13(4):199-206. PubMed ID: 19946345
[TBL] [Abstract][Full Text] [Related]
45. Promoter Methylation of BRCA1, DAPK1 and RASSF1A is Associated with Increased Mortality among Indian Women with Breast Cancer.
Yadav P; Masroor M; Nandi K; Kaza RCM; Jain SK; Khurana N; Saxena A
Asian Pac J Cancer Prev; 2018 Feb; 19(2):443-448. PubMed ID: 29480000
[TBL] [Abstract][Full Text] [Related]
46. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.
Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ
Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007
[TBL] [Abstract][Full Text] [Related]
47. Association between RASSF1A promoter methylation and prostate cancer: a systematic review and meta-analysis.
Pan J; Chen J; Zhang B; Chen X; Huang B; Zhuang J; Mo C; Qiu S
PLoS One; 2013; 8(9):e75283. PubMed ID: 24073258
[TBL] [Abstract][Full Text] [Related]
48. Prognostic value of RASSF1A methylation status in non-small cell lung cancer (NSCLC) patients: A meta-analysis of prospective studies.
Hu H; Zhou Y; Zhang M; Ding R
Biomarkers; 2019 May; 24(3):207-216. PubMed ID: 30764677
[No Abstract] [Full Text] [Related]
49. Hypermethylation of the RASSF1A tumor suppressor gene in Japanese clear cell renal cell carcinoma.
Tokinaga K; Okuda H; Nomura A; Ashida S; Furihata M; Shuin T
Oncol Rep; 2004 Oct; 12(4):805-10. PubMed ID: 15375503
[TBL] [Abstract][Full Text] [Related]
50. Role of RASSF1A promoter methylation in the pathogenesis of ovarian cancer: a meta-analysis.
Si JG; Su YY; Han YH; Chen RH
Genet Test Mol Biomarkers; 2014 Jun; 18(6):394-402. PubMed ID: 24665911
[TBL] [Abstract][Full Text] [Related]
51. Aberrant Methylation of RASSF1A gene Contribute to the Risk of Renal Cell Carcinoma: a Meta-Analysis.
Yu GS; Lai CY; Xu Y; Bu CF; Su ZX
Asian Pac J Cancer Prev; 2015; 16(11):4665-9. PubMed ID: 26107221
[TBL] [Abstract][Full Text] [Related]
52. Association between RASSF1A promoter methylation and renal cell cancer susceptibility: a meta-analysis.
Huang YQ; Guan H; Liu CH; Liu DC; Xu B; Jiang L; Lin ZX; Chen M
Genet Mol Res; 2016 Apr; 15(2):. PubMed ID: 27173228
[TBL] [Abstract][Full Text] [Related]
53. Hypermethylation-modulated downregulation of RASSF1A expression is associated with the progression of esophageal cancer.
Mao WM; Li P; Zheng QQ; Wang CC; Ge MH; Hu FJ; Fang XH; Dong ZM; Ling ZQ
Arch Med Res; 2011 Apr; 42(3):182-8. PubMed ID: 21722812
[TBL] [Abstract][Full Text] [Related]
54. RASSF1A promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis.
Peters I; Rehmet K; Wilke N; Kuczyk MA; Hennenlotter J; Eilers T; Machtens S; Jonas U; Serth J
Mol Cancer; 2007 Jul; 6():49. PubMed ID: 17634119
[TBL] [Abstract][Full Text] [Related]
55. Promoter hypermethylation of the tumor-suppressor genes RASSF1A, GSTP1 and CDH1 in endometrial cancer.
Fiolka R; Zubor P; Janusicova V; Visnovsky J; Mendelova A; Kajo K; Lasabova Z; Plank L; Danko J
Oncol Rep; 2013 Dec; 30(6):2878-86. PubMed ID: 24068440
[TBL] [Abstract][Full Text] [Related]
56. Prognostic significance of DAPK and RASSF1A promoter hypermethylation in non-small cell lung cancer (NSCLC).
Niklinska W; Naumnik W; Sulewska A; Kozłowski M; Pankiewicz W; Milewski R
Folia Histochem Cytobiol; 2009; 47(2):275-80. PubMed ID: 19926549
[TBL] [Abstract][Full Text] [Related]
57. Promoter methylations of RASSF1A and p16 is associated with clinicopathological features in lung cancers.
Han JC; Xu F; Chen N; Qi GB; Wei YJ; Li HB; Zhang YJ; Li JH; Wang XL; Xu W; Li XF; Jin LF; Jia JY; Ma ZS
J Cancer Res Ther; 2016; 12(1):340-9. PubMed ID: 27072261
[TBL] [Abstract][Full Text] [Related]
58. Prognostic role of APC and RASSF1A promoter methylation status in cell free circulating DNA of operable gastric cancer patients.
Balgkouranidou I; Matthaios D; Karayiannakis A; Bolanaki H; Michailidis P; Xenidis N; Amarantidis K; Chelis L; Trypsianis G; Chatzaki E; Lianidou ES; Kakolyris S
Mutat Res; 2015 Aug; 778():46-51. PubMed ID: 26073472
[TBL] [Abstract][Full Text] [Related]
59. Detection of RASSF1A promoter hypermethylation in serum from gastric and colorectal adenocarcinoma patients.
Wang YC; Yu ZH; Liu C; Xu LZ; Yu W; Lu J; Zhu RM; Li GL; Xia XY; Wei XW; Ji HZ; Lu H; Gao Y; Gao WM; Chen LB
World J Gastroenterol; 2008 May; 14(19):3074-80. PubMed ID: 18494062
[TBL] [Abstract][Full Text] [Related]
60. Quantitative analysis of RASSF1A promoter methylation in hepatocellular carcinoma and its prognostic implications.
Xu B; Di J; Wang Z; Han X; Li Z; Luo X; Zheng Q
Biochem Biophys Res Commun; 2013 Aug; 438(2):324-8. PubMed ID: 23891693
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
